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Aims: Liver glycogen catabolismwas evaluated inmale Swiss mice fed a high-fat diet rich in saturated fatty acids
(HFD) or normal fat diet (NFD) during one week.
Mainmethods: Liver glycogenolysis (LG) and liver glucose production (LGP)weremeasured either under basal or
stimulated conditions (infusion of glycogenolytic agents). Thus, isolated perfused livers from HFD and NFDmice
were infusedwith glycogenolytic agents, i.e., glucagon, epinephrine, phenylephrine, isoproterenol, adenosine-3′-
5′-cyclic monophosphate (cAMP), N6,2′-O-dibutyryl-cAMP (DB-cAMP), 8-bromoadenosine-cAMP (8-Br-cAMP)
or N6-monobutyryl-cAMP (N6-MB-cAMP). Moreover, glycemia and liver glycogen content were measured.
Key ﬁndings: Glycemia, liver glycogen content and basal rate of LGP and LG were not inﬂuenced by the HFD.
However, LGP and LG were lower (p b 0.05) in HFD mice during the infusions of glucagon (1 nM), epinephrine
(20 μM) or phenylephrine (20 μM). In contrast, the activation of LGP and LG during the infusion of isoproterenol
(20 μM) was not different (HFD vs. NFD). Because glucagon showed the most prominent response, the effect of
cAMP, its intracellular mediator, on LGP and LG was investigated. cAMP (150 μM) showed lower activation
of LGP and LG in the HFD group. However, the activation of LGP and LG was not inﬂuenced by HFD whether
DB-cAMP (3 μM), 8-Br-cAMP (3 μM) or N6-MB-cAMP (3 μM) were used.
Signiﬁcance: The activation of LGP and LG depends on the intracellular availability of cAMP. It can be concluded
that cAMP played a pivotal role on the activation of LG in high-fat diet fed mice.© 2014 Elsevier Inc. All rights reserved.Introduction
High-fat diet rich in saturated fatty acids raises the occurrence of
obesity, type 2 diabetes and cardiovascular disease (Azain, 2004; de
Lorgeril and Salen, 2012; Hoefel et al., 2011).Much of our knowledge as-
sociated with the deleterious effects of this diet comes from studies car-
ried out in experimental models, particularly in mice (Araújo et al.,
2007; Barrena et al., 2014; Haida et al., 2012;Masi et al., 2012). In a pre-
vious study, we demonstrated increased body weight, hypercholester-
olemia and fasting hyperglycemia in mice after 8 weeks of consuming
a high-fat diet rich in saturated fatty acids. However, some of these ef-
fects were observed earlier. For example, liver gluconeogenesis fromology and Therapeutics, State
.: +55 44 3011 5161.lactate increases already after one week of consuming this diet (Obici
et al., 2012).
A wide variety of factors regulate liver responsiveness to glycogeno-
lytic agents. The liver response to agents that promote glycogen catabo-
lism has been reported to change with animal species (García-Sáinz
et al., 1995), fasting (Melançon et al., 2013), physical exercise
(Melançon et al., 2013), adrenalectomy (García-Sáinz et al., 1989), hy-
pothyroidism (García-Sáinz et al., 1989), partial hepatectomy (García-
Sáinz et al., 1989), gender (Moriyama et al., 1997), feeding schedule
(Bazotte et al., 1989), insulin and leptin infusion (Borba-Murad et al.,
2004), pregnancy (Connolly et al., 2004), streptozotocin induced diabe-
tes (Stümpel et al., 1996), Walker-256 tumor (Morais et al., 2012),
hypercortisolism (Tavoni et al., 2013), hypoglycemia (Nascimento
et al., 2008) and aging (Jin, 2010; Muscogiuri et al., 2011).
A considerable amount of information has been accumulated on the
effect of high-fat diet rich in saturated fatty acids on liver glucose pro-
duction from gluconeogenesis, (An et al., 2013; Barrena et al., 2014;
Haida et al., 2012; Jin et al., 2013; Meng et al., 2013; Obici et al., 2012;
Fig. 1.Demonstrative experiments of the activation of glycogenolysis (●) and inhibition of
glycolysis (■) during the infusion of cAMP (150 μM) in perfused livers from fed mice
treated during one week with normal fat diet (NFD group). The perfusate was sampled
at 2-min intervals and analyzed for glucose, pyruvate and L-lactate. Glycogenolysis and
glycolysis were calculated as described in the Material and methods section. The area
under the curves (AUC) was obtained from the difference between the values during
and before the infusion of cAMP and was expressed as μmol·g−1. The data are reported
as the mean ± SD of 6 individual liver perfusion experiments. The negative values repre-
sent the inhibition glycolysis during the infusion of cAMP in comparisonwith basal values.
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regarding liver glycogen catabolism under this condition (Jin et al.,
2013; Pocai et al., 2005; Potthoff et al., 2013).
Considering that the activation of liver gluconeogenesis was ob-
served one week after starting HFD (Obici et al., 2012). In this study
we investigate the activation of liver glycogen catabolism in mice sub-
mitted to high-fat diet during the same period of time. The response
to cAMPwas also examined since this intracellular signalingmessenger
plays a key role in the action of several hormones including glucagon
and epinephrine.
Material and methods
List of chemical compounds
Glucagon (Glucagen®) and epinephrine (Adren®) were obtained
from Novo Nordisk (São Paulo, Brazil) and Hipolabor (Santa Luzia,
Brazil), respectively. Adenosine-3′-5′-cyclic monophosphate (cAMP),
N6,2′-O-Dibutyryl-cAMP (DB-cAMP), 8-bromoadenosine-cAMP (8-Br-
cAMP), N6-monobutyryl-cAMP (6-MB-cAMP), phenylephrine and iso-
proterenol were purchased from Sigma Chemical Company (St. Louis,
USA).
Animals and treatment
Male Swiss mice (Mus musculus) weighing about 35 g (6-wk old)
were used. The experimental protocol was approved by the ethics com-
mittee and followed the international law on the protection of animals.
The mice were maintained under constant temperature (22 ± 1 °C)
with automatically controlled photoperiod (12 h light/12 h dark) and
free access to water and food.
The mice were randomly divided in two groups. The experimental
group received a high-fat diet rich in saturated fatty acids (HFD
group) and the control group received normal fat diet (NFD group) dur-
ing one week.
The composition of the normal fat diet was based on that of puriﬁed
diets for laboratory rodents proposed by the American Institute of Nu-
trition (Reeves et al., 1993) for adult maintenance (AIN-93-M).
The amounts (g·100 g−1) of protein, carbohydrate, total fat and sat-
urated fatty acids in theNFDwere 14.2, 73.8, 4 and1.5, respectively, that
is, 3.8 kcal·g−1 (total amount). In addition, the amounts (g·100 g−1) of
protein, carbohydrate, total fat and saturated fatty acids in the HFD diet
were 20.3, 36.5, 35.2 and 12.9, respectively, that is, 5.8 kcal·g−1
(total amount). Details about the composition of these diets can be
found in our previous work (Barrena et al., 2014).
Experimental protocol
Considering that the fed state is a favorable condition to study liver
glycogen catabolism (Carrara et al., 2012; Nascimento et al., 2008), fed
mice that received HFD or NFD diet during oneweekwere anesthetized
using intraperitoneal ketamine/xylazine (60/12 mg·kg−1 b.w.). After
laparotomy, the blood was collected from the cava vein for glucose de-
termination and liver perfusion was immediately initiated.
Liver perfusion experiments were performed in an open
system without perfusate recirculation. The perfusion ﬂuid, Krebs–
Henseleit buffer, pH 7.4, saturated with an oxygen/carbon dioxide mix-
ture (95/5%) was pumped through a temperature regulated (37 °C)
membrane oxygenator prior to entering the liver via a cannula inserted
in the portal vein.
When isolated livers are perfused in a non-recirculating systemwith
medium containing no glucose, L-lactate or pyruvate, these products are
washed out due to the high concentration gradients between cytosol
and extracellular ﬂuid. This technique is suitable since metabolites
do not accumulate. Metabolite production can be determined
directly from the metabolite concentration in the efﬂuent perfusate(García-Sáinz et al., 1995). Therefore, the release of glucose, pyruvate
and L-lactate reﬂects almost quantitatively the glycogen breakdown.
This artiﬁcial condition provides the basal rates of liver catabolism
that can be intensiﬁed with the infusion of glycogenolytic agents.
The glycogenolytic agents used in the experiments were: glucagon
(1 nM), epinephrine (20 μM), phenylephrine (20 μM), isoproterenol
(20 μM), cAMP (150 μM), DB-cAMP (3 μM), 8-Br-cAMP (3 μM) and
N6-MB-cAMP (3 μM). The concentrations used were deﬁned through
preliminary experiments of dose response curve (not shown).
Typical liver perfusion experiments are illustrated in Fig. 1. Follow-
ing a preinfusion period (0–10 min), the glycogenolytic agents were
dissolved in the perfusion ﬂuid and infused for 20 min (10–30 min).
This was followed by a period of post-infusion (30–40 min) to allow
the return to basal levels. Samples of the efﬂuent perfusion ﬂuid were
collected at 2-min intervals and the levels of glucose (Bergmeyer and
Bernt, 1974), pyruvate (Czok and Lamprecht, 1974) and L-lactate
(Gutmann and Wahlefeld, 1974) in the efﬂuent perfusate were
analyzed.
Assuming that glucose, pyruvate and L-lactate released into the per-
fusate are themain products of glycogen catabolism, glycogenolysiswas
calculated by the sumof glucose plus the half-sumof L-lactate and pyru-
vate [glucose + ½ (L-lactate + pyruvate)]. The release of these metab-
olites provides a good approximation to the rate of glycogenolysis
because pyruvate oxidation, pentose-monophosphate shunt and
recycling of pyruvate to glucose are minimal (Kimmig et al., 1983). In
addition, glycolysis was calculated by the sum of L-lactate plus pyruvate
(L-lactate + pyruvate). At the end of the experiment the liver was re-
moved and weighed, to allow precise metabolic calculations and the
correction of ﬂow rates. The values obtained were expressed as
μmol·min−1·g−1.
The activation of glycogen catabolism was estimated by the differ-
ence between the rates of glucose, pyruvate and L-lactate production,
glycolysis and glycogenolysis during and before the infusion of glyco-
genolytic agents.
The differences allowed us to calculate and compare the areas under
the curves (AUCs) for all groups investigated (expressed as μmol·g−1).
Moreover, the basal rates of glucose, pyruvate and L-lactate production,
glycolysis and glycogenolysis, before the activation of glycogen catabo-
lism (0–10 min) were calculated by the AUC analysis, as previously
described.
Table 1
Bodyweight, epididymal fatweight, retroperitoneal fat weight, inguinal fatweight andmesenteric fat weight ofmice previously treatedwith either a normal fat diet (NFD group) or high-
fat diet rich in saturated fatty acids (HFD group) during one week.
Initial Final Epididymal Retroperitoneal Inguinal Mesenteric
Body weight Body weight Fat weight Fat weight Fat weight Fat weight
NFD 35.6 ± 0.87 40.7 ± 2.0 0.86 ± 0.15 0.30 ± 0.06 0.84 ± 0.16 0.41 ± 0.10
HFD 35.5 ± 1.1 39.7 ± 2.4 0.98 ± 0.24⁎ 0.32 ± 0.07 0.93 ± 0.23⁎ 0.38 ± 0.10
Values (g) are expressed as the means ± standard deviation of 43 mice.
⁎ p b 0.05 (NFD vs. HFD).
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scribed above. However, immediately after the period of 10min of infu-
sion in the absence of glycogenolytic agent (0–10 min), the livers were
removed and immediately frozen in liquid nitrogen for determination of
liver glycogen content (Kepler and Decker, 1974).
Finally, epididymal, retroperitoneal, mesenteric and inguinal fat de-
pots were removed and weighed.Statistical analysis
Statistical analyses were performed by an unpaired Student's t-test,
using the Graph-Pad Prism software (version 5.0). Results were report-
ed asmeans± standard deviation (SD). The p b 0.05 level of probability
was accepted as statistically signiﬁcant difference for all comparisons.Results
The HFD group showed higher (p b 0.05) epididymal and inguinal
fat pad weights. However, there was no difference between the HFD
and NFD groups in the body weight, retroperitoneal or mesenteric fat
pad weight (Table 1).
Glycemia (Table 2), liver glycogen content (Table 2) and the rate
of glycogen catabolism before the infusion of the glycogenolytic
agents (Table 3) were not affected by the HFD but pyruvate production,
L-lactate production, and glycolysis were lower (p b 0.05) in the HFD
group (Table 3).
The activation of liver glucose production and glycogenolysis by glu-
cagon, epinephrine and phenylephrine was clearly less pronounced in
the liver of the HFD as compared to NFD groups (Table 4). In contrast,
the activation of liver glucose production and glycogenolysis during
the infusion of isoproterenol was not different (Table 4). Moreover,
the infusion of glucagon or isoproterenol promoted marked inhibition
of liver glycolysis in HFD mice (Table 4).
Since glucagon showed themost prominent effects on liver glycogen
catabolism and considering that the effects of this hormone are mediat-
ed by cAMP, the effects of the direct infusion of cAMP on liver glycogen
catabolism were evaluated.
During the infusion of cAMP (150 μM) lower (p b 0.05) intensiﬁca-
tion of liver glucose production and glycogenolysis was observed in
the HFD group (Table 5). However, the intensiﬁcation of liver glucose
production and of glycogenolysis was not inﬂuenced by HFD whether
DB-cAMP (3 μM), 8-Br-cAMP (3 μM) or N6-MB-cAMP (3 μM) were
used as glycogenolytic agents.Table 2
Glycemia (mg·dL−1) and hepatic glycogen concentration (μmol·dL−1) ofmice previously
treated with either a normal fat diet (NFD group) or high-fat diet rich in saturated fatty
acids rich in saturated fatty acids (HFD group) during one week.
Glycemia Liver glycogen
NFD 257.7 ± 29.3 (33) 618.6 ± 13.3 (7)
HFD 258.4 ± 28.9 (33) 634.2 ± 46.6 (7)
Values are expressed as the means ± standard deviation.
( ) Number of animals.Discussion
The effect of HFD on glucose, pyruvate, L-lactate liver production,
glycolysis and glycogenolysis before and during the infusions of glyco-
genolytic agents was evaluated in livers of fed mice. For this purpose
in situ perfused livers were used. In contrast with isolated hepatocytes
or cell culture, the perfusion of liver in situ allows to study the
effects of drugs and hormones under condition of preserved physiolog-
ically relevant signaling pathways (Hue and Taegtmeyer, 2009;
Vardanega-Peicher et al., 2003).
All data obtained in the experiments in which glucagon, epineph-
rine, phenylephrine and isoproterenol were infused are condensed in
Table 4. The results showed that both glucagon and isoproterenol inhib-
it glycolysis. However, this effect was more pronounced by glucagon,
probably because this hormone has a higher ability to elevate the intra-
cellular cAMP levels in comparison with isoproterenol (Vardanega-
Peicher et al., 2003).
In contrast with our previous investigation for gluconeogenesis
(Obici et al., 2012), the liver responsiveness to glucagon, epinephrine
and phenylephrine for glucose production and glycogenolysis was de-
creased (pb 0.05) in theHFDmice (Table 4). These results cannot be ex-
plained by the liver glycogen content (Table 2), the basal rates of
glucose production or glycogenolysis (Table 3). In fact, these parameters
remained unchanged in livers of HFD mice.
The data from glucagon and phenylephrine are relevant due to the
fact that liver receptors for these substances play an important role for
their effect in a large number of experimental (Charbonneau et al.,
2005, 2007; Fraeyman et al., 2000; Ghosh et al., 2012) and clinical con-
ditions (Hwang et al., 1994; Shah et al., 2000).
Lower (p b 0.05) responsiveness to glucagon, epinephrine and
phenylephrine on glycogen catabolism associated with no change in
blood glucose concentration (Table 2) was observed in the HFD mice
under fed state. Possibly the decreased responsiveness to these glyco-
genolytic agents was compensated by an increased liver gluconeogene-
sis as we previously demonstrated (Obici et al., 2012). In agreement
with this postulation, we observed higher glycemia (p b 0.05) in over-
night fastedmice, a physiological condition where gluconeogenic activ-
ity is stimulated (155.7 ± 24.6 mg·dL−1, n = 6, HFD group vs. 91.6 ±
8.9 mg·dL−1, n = 6, NFD group).
Due to the fact that the most pronounced changes in the activation
of liver glycogen breakdown were observed for glucagon and consider-
ing that cAMP is the secondmessenger of glucagon, the effect of this cy-
clic nucleotide was tested.Table 3
Basal rates of glucose, L-lactate and pyruvate production, glycolysis and glycogenolysis in
livers frommice fed with either a normal fat diet (NFD group) or high-fat diet rich in sat-
urated fatty acids (HFD group) during one week.
Glucose L-Lactate Pyruvate Glycolysis Glycogenolysis
NFD 20.8 ± 3.9 19.3 ± 2.1 1.3 ± 0.5 19.7 ± 3.3 29.6 ± 4.6
HFD 20.2 ± 4.4 13.4 ± 3.2⁎ 0.44 ± 0.29⁎ 13.9 ± 4.2⁎ 27.0 ± 5.4
Values are expressed as mean ± standard deviation of area under the curve (μmol·g−1)
obtained from 6–8 experiments, as described in Fig. 1.
⁎ p b 0.05 (NFD vs. HFD).
Table 4
Glucose, L-lactate and pyruvate production, glycolysis and glycogenolysis during the infusion of glucagon (1 nM), epinephrine (20 μM), phenylephrine (20 μM) or isoproterenol (20 μM)
in livers from mice fed with either a normal fat diet (NFD group) or high-fat diet (HFD group) during one week.
Glucagon Epinephrine Phenylephrine Isoproterenol
NFD HFD NFD HFD NFD HFD NFD HFD
Glucose 76.3 ± 13.8 24.7 ± 5.2⁎ 53.3 ± 12.7 27.6 ± 4.3 ⁎ 16.9 ± 6.3 6.7 ± 1.3 ⁎ 11.3 ± 4.2 16.3 ± 6.9
L-Lactate −1.7 ± 2.2 −7,5 ± 3,2⁎ 4.1 ± 0.86 4.2 ± 1.0 3.1 ± 1.6 1.2 ± 0.48⁎ −5.5 ± 2.8 −10.4 ± 3.0⁎
Pyruvate −1.0 ± 0.28 −0.54 ± 0.25⁎ −0.52 ± 0.49 −0.36 ± 0.18 −0.50 ± 0.2 −0.05 ± 0.03⁎ −0.47 ± 0.18 −0.34 ± 0.14
Glycolysis −2.7 ± 2.1 −8.1 ± 3.6⁎ 3.7 ± 1.3 4.3 ± 0.8 2.5 ± 1.7 1.0 ± 0.27 −6.4 ± 2.2 −10.9 ± 1.7⁎
Glycogenolysis 75.2 ± 14.4 20.5 ± 5.8 ⁎ 55.9 ± 14.1 29.0 ± 4.6 ⁎ 21.0 ± 7.4 6.2 ± 2.6⁎ 8.3 ± 2.6 11.6 ± 4.4
Values are expressed as mean ± standard deviation of area under the curve (μmol·g−1) obtained from 6–8 experiments, as described in Fig. 1.
The negative values represent the inhibition of pyruvate production, L-lactate production and glycolysis during the infusion of glucagon, epinephrine, phenylephrine and isoproterenol in
comparison with basal values.
⁎ p b 0.05 (NFD vs. HFD).
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is difﬁcult to estimate howmuch of the infused amount permeate liver
cellmembrane increasing the intracellular levels of cAMP that is propor-
tional to the extracellular concentration used in the liver perfusion me-
dium (Hwang et al., 1994; Vicentini et al., 2000). For this reason, the
livers were infused with increasing concentrations of cAMP until it
reaches the maximal response for the activation of glycogenolysis and
inhibition of glycolysis, i.e., 150 μM (results not shown).
The results demonstrate that cAMP (150 μM) was less effective
(p b 0.05) to promote the activation of glycogen catabolism and inhibi-
tion of glycolysis in livers of HFD mice compared to NFD (Table 5).
To gain more information about the role played by intracellular
levels of cAMP, the experiments were repeated with cAMP analogs
(DB-cAMP, 8-Br-cAMP or 6-MB-cAMP) that are metabolized at lower
rates by phosphodiesterases. For comparative purposes, the same con-
centration (3 μM) of each analog was used. Nevertheless, differently to
cAMP, the activation of glycogen breakdown and inhibition of glycolysis
promoted by DB-cAMP, 8-Br-cAMP or 6-MB-cAMP were not inﬂuenced
by HFD (Table 5). Possibly, the best explanation for these results is that
the activation of liver glycogen catabolism depends on the intracellular
availability of cAMP which was probably decreased in livers of HFD
mice.
Since the mechanisms beyond glucagon receptors and signal trans-
duction machinery play an important role to regulate liver glycogen ca-
tabolism by glucagon, we used cyanide, a respiratory chain inhibitor,
which bypasses membrane receptors to activate glycogenolysis and
glycolysis.
In contrast to glucagon, the responsiveness of glycogen breakdown in
the livers of HFDmice infusedwith cyanide remained unchanged (results
not shown). These results employing cyanide suggest that the signaling
machinery of the liver to mobilize glycogen is maintained in HFD mice.
A question can then be raised: how can we reconcile the lower acti-
vation of glycogen catabolism during infusion of glucagon or cAMPwith
the concept that HFD promote insulin resistance and type 2 diabetes?Table 5
Glucose, L-lactate and pyruvate production, glycolysis and glycogenolysis during the infusion o
bromoadenosine-cAMP (8-Br-cAMP) or N6-monobutyryl-cAMP (6-MB-cAMP) in livers frommi
(HFD group) during one week.
cAMP (150 μM) DB-cAMP (3 μM)
NFD HFD NFD HFD
Glucose 32.3 ± 8.0 4.7 ± 2.1⁎ 33.6 ± 11.6 28.7
L-Lactate −7.9 ± 2.3 −6.9 ± 2.0 −10.6 ± 1.2 −7.8
Pyruvate −0.52 ± 0.18 −0.23 ± 0.14 −1.2 ± 0.4 −0.49
Glycolysis −8.7 ± 2.4 −6.8 ± 1.4⁎ −11.7 ± 1.2 −8.1
Glycogenolysis 28.5 ± 7.3 2.0 ± 1.8⁎ 30.0 ± 12.5 24.3
The area under the curve values (μmol·g−1) was obtained as described in Fig. 1 and was expre
The negative values represent the inhibition of pyruvate production, L-lactate production and gl
with basal values.
⁎ p b 0.05 (NFD vs. HFD).The explanation for this apparent discrepancy includes the fact that
the cAMP concentration in the hepatocytes is regulated in an opposite
manner by glucagon/adenylate cyclase and insulin/phosphodiesterase
3B (PDE3B).
The binding of glucagon to their receptors in the hepatocytes leads
to the activation of adenylate cyclase that promotes the conversion of
ATP to cAMP.
On the other hand, the binding of insulin to its receptor triggers
a signaling pathway that involves insulin substrate receptors that
promotes the activation of downstream target molecules including
phosphoinositide 3-kinases (PI3K). Active PI3K phosphorylates
phosphatidylinositol-4,5-biphosphate to phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3, in turn, recruits and activates further down-
stream molecules such as protein kinase B (PKB)/AKT and PDE3B, the
main cAMP-degrading enzyme in the liver.
Therefore, although glucagon and insulin receptors are structurally
distinct they share cAMP as a common molecule in their signal trans-
duction pathways.
Considering that cAMP showed lower effects on liver glycogen
catabolism, we can suggest that the process of inactivation of cAMP
overcomes its formation in HFD group. In agreement with this postula-
tion, HFD mice showed higher epididymal and inguinal fat weight
(Table 1). These paradoxal effects are referred as selective insulin resis-
tance (Brown and Goldstein, 2008). However, it should be emphasized
that oneweek of HFDmay not be sufﬁcient to induce the typical insulin
resistance state seen in animals fed the same diet for 8 weeks (Araújo
et al., 2007).
The results led us to postulate that the convergent signaling path-
ways for the control of liver glycogen catabolism in mice submitted to
HFD probably involve a reduction in the intracellular concentration of
cAMP. Thus, cAMP levels may play an important role for the lower ef-
fects of glucagon in high-fat mice.
It can be concluded that cAMP played a pivotal role on the activation
of liver glycogen breakdown in high-fat diet fed mice.f adenosine-3′-5′-cyclic monophosphate (cAMP), N6,2′-O-Dibutyryl-cAMP (DB-cAMP), 8-
ce fedwith either a normal fat diet (NFD group) or high-fat diet rich in saturated fatty acids
8-Br-cAMP (3 μM) 6-MB-cAMP (3 μM)
NFD HFD NFD HFD
± 11.4 17.1 ± 1.4 22.5 ± 8.0 19.7 ± 9.2 18.6 ± 3.9
± 2.9 −16.4 ± 2.0 −7.4 ± 8.1⁎ −5.2 ± 2.6 −6.4 ± 1.6
± 0.23 −1.3 ± 0.5 −0.5 ± 0.34⁎ −0.4 ± 0.2 −0.3 ± 0.1
± 2.9 −17.8 ± 1.4 −7.3 ± 2.9⁎ −5.1 ± 3.3 −6.8 ± 2.0
± 11.62 13.2 ± 5.8 17.0 ± 6.2 16.8 ± 8.5 11.8 ± 7.5
ssed as the mean ± standard deviation from 6–8 experiments.
ycolysis during the infusion of cAMP, DBc-cAMP, 8-Br-cAMP or 6-MB-cAMP in comparison
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